Skip to main content
Smart Investors Daily
ZL

NASDAQ · ZLAB

Zai Lab Limited

Healthcare · Biotechnology

$21.03

Down-$0.89 (-4.06%)

Updated Nov 22, 2026, 4:59 PM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.97B
P/E ratio
-9.41
Dividend yield
0.00%
52-week range
$15.96 – $29.02
Volume
1.44M
Avg. volume
828.59K

Price performance · ZLAB

ZLAB price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

ZLAB closed at $21.03 after 20 trading sessions, down 13.60% for the selected period.

Last close
$21.03
Period change
-13.60%
Period low
$21.03
Period high
$26.86
Daily close
View OHLC price history
ZLAB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$20.99$21.15$20.02$21.031.44M
Nov 19, 2026$21.94$22.27$21.695$21.92611.43K
Nov 18, 2026$23.00$23.20$22.04$22.111.04M
Nov 17, 2026$23.61$23.98$23.05$23.53690.59K
Nov 16, 2026$24.16$24.415$22.83$23.47735.44K
Nov 13, 2026$25.75$25.935$23.43$24.601.22M
Nov 12, 2026$26.57$26.75$25.84$26.04859.42K
Nov 11, 2026$25.93$26.50$25.30$26.42920.48K
Nov 10, 2026$27.19$27.19$26.15$26.431.53M
Nov 9, 2026$27.15$29.02$26.52$26.862.1M
Nov 6, 2026$23.55$25.99$23.35$25.481.89M
Nov 5, 2026$22.91$23.035$22.01$22.60814.02K
Nov 4, 2026$23.17$23.40$22.26$22.801.17M
Nov 3, 2026$21.65$22.28$21.4176$21.962.52M
Nov 2, 2026$22.15$22.15$21.50$21.665473.89K
Oct 30, 2026$22.30$22.425$21.80$22.07637.84K
Oct 29, 2026$22.77$22.85$22.135$22.36648.51K
Oct 28, 2026$23.33$23.49$22.63$23.04704.06K
Oct 27, 2026$23.10$23.805$22.44$23.581.54M
Oct 26, 2026$24.38$24.39$23.02$24.341.74M

Latest ZLAB news

The latest Smart Investors Daily articles mentioning ZLAB.

ZLAB research

Overview

Company profile and research snapshot.

Company profile

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$75.00
Implied upside
—
Analysts
—
ZLAB recent ratings
DateFirmRatingTarget
Sep 10, 2020SVB LeerinkOutperform—
Dec 30, 2019CitigroupBuy—
Sep 4, 2019China RenaissanceBuy—
Jul 5, 2019MacquarieOutperform—
Jan 29, 2019Credit SuisseOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 14, 2026

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China's 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country's 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease.

Yahoo · Nov 14, 2026

Zai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth Products

SHANGHAI & CAMBRIDGE, Mass., November 14, 2026--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that five of its commercial medicines in China have been included in the country’s 2026 National Reimbursement Drug List (NRDL). The update includes two first-time listings, expanding patient access to treatments for gMG and schizophrenia, and three renewals, which maintain access across oncology and infectious disease.

Yahoo · Nov 13, 2026

Zai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing

Zai Lab Limited (NASDAQ:ZLAB) reported preliminary results from the first-in-human portion of its global Phase 1/1b clinical trial evaluating ZL-1503, an investigational bispecific antibody for moderate-to-severe atopic dermatitis. Strong Biomarker Inhibition And Extended Half-Life Data from 48 healthy volunteers showed that ZL-1503 rapidly and sustainably blocked the IL-13 pathway. A single dose of 200 mg or higher inhibited phosphorylated STAT6, a key atopic dermatitis signaling biomarker, by

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.